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Abstract
Obesity and adipose-derived peptides might be involved in the pathogenesis of atrial 
fibrillation (AF). Adiponectin plays a major role in the modulation of several meta-
bolic pathways, and asymmetric dimethylarginine (ADMA) has been suggested to be 
predictive of AF and associated adverse events. The aim of this study was to inves-
tigate the effect of fish oil supplementation on circulating adiponectin and ADMA in 
overweight or obese patients with persistent AF. In this randomized, double-blind, 
placebo-controlled trial, 80 overweight or obese (body mass index (BMI) ≥ 25 kg/m2) 
patients with persistent AF were randomly assigned to two groups to receive either 
2 g/day fish oil or placebo, for 8 weeks. Serum levels of adiponectin and ADMA, and 
anthropometric indexes were measured. This study showed that serum adiponectin 
concentrations increased significantly following fish oil supplementation compared 
with the placebo group (13.15 ± 7.33 vs. 11.88 ± 6.94 µg/ml; p = .026). A signifi-
cant reduction was also observed in serum ADMA levels in the fish oil compared 
with the placebo group following the intervention (0.6 ± 0.13 vs. 0.72 ± 0.15 µmol/L; 
p = .001). The changes in serum adiponectin and ADMA concentrations remained 
significant after adjustments for baseline values, age, sex, and changes of BMI and 
waist circumference (p = .011 and p = .001, respectively). In conclusion,  8 weeks 
supplementation with fish oil increased serum adiponectin and decreased ADMA 
concentrations in overweight or obese patients with persistent AF. As adiponectin 
and ADMA are suggested to be involved in many pathways associated with AF, the 
current findings might be promising in the clinical management of this disease, an 
issue that needs further investigations.
K E Y W O R D S
adiponectin, asymmetric dimethylarginine, atrial fibrillation, fish oil, obesity
2166  |     KHORRAMI et Al.
1  | INTRODUC TION
Atrial fibrillation (AF) is the most common form of arrhythmia, 
which could increase the risk of stroke and thromboembolic events 
(Go et al., 2001). It was estimated that 2.3 million people were af-
fected by AF in the United States in 2001, which will increase to 
more than 5.6 million by the year 2050 (Go et al., 2001). Obesity 
is considered as an independent risk factor of short- and long-
term incidence of AF. Each unit increase in body mass index (BMI) 
was associated with about 4% increased risk of AF (Tedrow et al., 
2010; Wang et al., 2004). Obesity might contribute to AF through 
mechanisms such as inflammation and oxidative stress, insulin 
resistance, changes in metabolic by-products such as advanced 
glycation end products and related disturbances in myocardial me-
tabolism, which are correlated with atrial structural and functional 
abnormalities (Abed & Wittert, 2013; Goudis, Korantzopoulos, 
Ntalas, Kallergis, & Ketikoglou, 2015). Endothelial dysfunction is 
another obesity-associated disorder that might contribute to AF 
(O'Neal et al., 2014).
Other factors such as hypertension and epicardial fat might also 
contribute to atrial electro-structural dysfunction (Abed & Wittert, 
2013; Goudis et al., 2015). Epicardial fat has strong relationship 
with BMI and especially with visceral adipose tissue (Rabkin, 2014). 
Adipose tissue produces lots of bioactive molecules or adipocyto-
kines, which are involved in different physiological and pathophysio-
logical pathways. Adiponectin is a major adipokine with well-known 
insulin-sensitizing, anti-inflammatory, antiproliferative, and anti-ath-
erogenic properties (Ouchi, Parker, Lugus, & Walsh, 2011). Lower 
release of epicardial adiponectin was associated with development 
of AF after cardiac surgery (Kourliouros et al., 2011). Circulating ad-
iponectin was significantly lower in AF compared to controls with 
normal sinus rhythm (Choi et al., 2012), and was inversely associated 
with major cardiovascular events in women with AF (Hernández-
Romero et al., 2013). Asymmetric dimethylarginine (ADMA), a major 
inhibitor of nitric oxide (NO) synthase, is another peptide secreted by 
adipocytes (Spoto, Parlongo, Parlongo, Sgro, & Zoccali, 2007), which 
can induce endothelial dysfunction, inflammation, and oxidative 
stress in cardiovascular disorders (Bouras et al., 2013). ADMA lev-
els were significantly higher in AF compared to non-AF individuals 
candidate for coronary angiography (Chao et al., 2013) and healthy 
controls (Cengel et al., 2008). Higher ADMA levels were associated 
with increased risk of AF recurrence following electrical cardiover-
sion (Xia et al., 2008) and catheter ablation (Yang et al., 2011). It has 
been suggested that ADMA could have prognostic value in predict-
ing AF in high-risk patients (Stamboul et al., 2015). Besides, studies 
have indicated the predictive value of ADMA in determining the ad-
verse events such as mortality and stroke in AF (Chao et al., 2013; 
Horowitz et al., 2018).
Little is known about the effects of nutritional supplements on 
circulating levels of these biomarkers in patients with AF. Higher 
serum levels of long-chain omega-3 fatty acids have been linked with 
a lower incidence of AF (Virtanen, Mursu, Voutilainen, & Tuomainen, 
2009). Moreover, fish oil supplementation led to lower incidence of 
AF (Calò et al., 2005), duration of AF and ICU stay (Farahani et al., 
2017) after coronary artery bypass graft surgery (CABG).
However, studies investigating the effect of fish oil supplemen-
tation on these mediating factors are scarce in patients with AF. 
Thus, the aim of the current study was to examine the effect of fish 
oil supplementation on serum ADMA and adiponectin concentra-
tions in overweight or obese patients with persistent AF.
2  | MATERIAL S AND METHODS
2.1 | Study population
In the current randomized, double-blind, placebo-controlled, parallel 
design trial, 80 overweight or obese (25 ≤ BMI ≤ 40 kg/m2) patients 
with persistent AF, age ≥ 50 years, and on warfarin therapy were 
enrolled.
Patients with thyroid dysfunction, valvular heart disease, heart 
failure, and CABG in the past 3 months were not included. Besides, 
smokers, patients with a history of drug or alcohol abuse, those with 
recent acute illnesses and infectious diseases, woman with hormone 
replacement therapy, participants consuming fish oil derivatives in 
the past 3 months, or allergic to fish oil were not included in this 
study. Patients were excluded if they need CABG or did not con-
sume more than 10% of capsules. The sample size was calculated, 
considering adiponectin as the main variable, based on the formula 
for randomized clinical trials, with type I (a) error of 0.05 and type 
II error (b) of 0.20 (power = 80%). The calculation showed that 38 
participants in each group would be sufficient. Assuming a drop-
out of 10%, the final sample size was determined to be 42 patients 
in each group. Ethical Committee of Tehran University of Medical 
Sciences approved the study protocol, and informed written consent 
was obtained from all patients. This clinical trial was registered with 
a national registry system of clinical trials (Registration ID at irct.ir: 
IRCT2012110411362N1).
2.2 | Study design
Patients were assigned to two groups using random stratified per-
muted blocks. Two diabetes categories (yes/no) were considered as 
strata to eliminate the confounding effect of this disease. Patients 
were randomly assigned to two groups to receive either 2 g/day (two 
1,000-mg capsules) fish oil (each capsule contained 300 mg eicosa-
pentaenoic acid (EPA) and 200 mg docosahexaenoic acid (DHA)) or 
2 g/day olive oil as placebo for 8 weeks. Fish oil supplements and 
placebo were produced by Daana Company. The placebo and fish oil 
capsules were the same in size, weight, and color.
Patients were followed up by phone weekly. To assess compli-
ance, we asked the participants to bring back the empty box of the 
capsules at the end of the study. All patients were requested not to 
change their usual physical activity and dietary intakes throughout 
the study period and not to consume any additional supplement. A 
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3-day 24-hr dietary recall (two weekdays and one weekend) was 
completed to examine reported dietary intakes at baseline and fol-
lowing the intervention. Mean dietary intakes were analyzed using 
Nutritionist IV software (N Squared Computing) modified for some 
local foods.
2.3 | Assessment of variables
Anthropometric indices including height and weight were measured 
using Seca scale and tape (Germany) before and after the interven-
tion, with light clothing and no shoes. BMI was calculated as weight 
in kilograms divided by height in meters squared. Waist circumfer-
ence was measured between the lowest rib and the iliac crest, using 
a nonelastic tape. An overnight 10-ml fasting venous blood sample 
was taken at baseline and at the end of the trial. Samples were cen-
trifuged at 3,000 rpm for 15 min to separate serum and stored at 
−80°C until the analysis. Commercial enzyme-linked immunosorbent 
assay (ELISA) kits were used to quantify serum levels of adiponectin 
(Mediagnost) and ADMA (DLD). Intra- and interassay coefficients of 
variation were <10% for these measurements.
2.4 | Statistical methods
Normal distribution of the variables was assessed using the 
Kolmogorov–Smirnov test. Independent samples t test or Mann–
Whitney U test was applied to compare variables between the two 
groups at baseline. Chi-square test was used to compare categorical 
variables between the two groups. To examine the effect of sup-
plementation on main variables, we applied analysis of covariance 
(ANCOVA) adjusting for baseline measurements as well as, age, 
sex, and changes in BMI and waist circumference. p values were 
considered significant at the level of ˂.05. Statistical analysis was 




Four patients did not finish the study: two in the fish oil group due 
to personal reasons and two in the control group due to consum-
ing <10% of the capsules (n = 1) and death (n = 1) (Figure 1). No 
adverse effects were reported by patients after taking supplements 
or placebos.
General baseline characteristics of the study participants are 
shown in Table 1. No significant differences were observed in mean 
age, BMI, and waist circumference between the fish oil and placebo 
groups at baseline. Moreover, the prevalence of diabetes, hyperten-
sion, and hypercholesterolemia was not different between the two 
groups. Reported dietary intakes of energy, macronutrients, EPA, 
DHA, and α-linolenic acid (ALA) were not significantly different be-
tween the two groups at baseline (Table 1). Besides, there were no 
considerable differences in reported dietary intakes at the end of 
the study.
3.2 | ADMA and adiponectin
Serum adiponectin concentrations increased significantly fol-
lowing fish oil supplementation compared with the control group 
(13.15 ± 7.33 vs. 11.88 ± 6.94 µg/ml, p = .026). Furthermore, a 
significant reduction was observed in serum ADMA levels in the 
fish oil compared with the control group following the interven-
tion (0.6 ± 0.13 vs. 0.72 ± 0.15 µmol/L, p = .001). Changes in serum 
adiponectin and ADMA remained significant after adjustment for 
baseline values, age, sex, changes of BMI and waist circumference 
(p = .011 and p = .001, respectively) (Table 2).
3.3 | Anthropometric changes
Weight (0.99 ± 1.97 vs. 0.06 ± 1.74 kg, p = .029), BMI (0.40 ± 0.84 vs. 
0.03 ± 0.7 kg/m2, p = .029), and waist circumference (2.42 ± 2. 15 vs. 
0.1 ± 1.34 cm, p < .001) were significantly decreased in the fish oil 
compared to the control group (Table 3).
4  | DISCUSSION
In this randomized, placebo-controlled, parallel design clinical trial, 
2 g/daily fish oil supplementation for 8 weeks had a significant 
effect on increasing adiponectin and decreasing ADMA serum 
concentrations.
The effect of n-3 polyunsaturated fatty acids on increasing cir-
culating adiponectin has been well recognized in experimental and 
clinical models (Flachs et al., 2006; Itoh et al., 2007). However, lit-
tle is known about the effect of these fatty acids on adiponectin in 
AF. EPA treatment (300 mg/kg daily for 4 weeks) in a rabbit model 
declined the increased duration of AF and atrial fibrosis associated 
with heart failure. This change was accompanied with increased 
adiponectin and decreased tumor necrosis factor alpha (TNF-α) ex-
pression in the atrium and epicardial adipose tissue (Kitamura et al., 
2011). A clinical study showed neither a difference in the incidence 
of postcardiac surgery AF nor a change in adiponectin concentration 
compared to controls following 900 mg daily consumption of EPA for 
3–6 months (Yamamoto et al., 2014).
Left ventricular (LV) hypertrophy is a risk factor for AF devel-
opment (Healey & Connolly, 2003). In an animal study of LV hyper-
trophy, adiponectin levels increased significantly in both normal 
low-fat and high-fat diets supplemented with fish oil (2.3% of energy 
intake as EPA + DHA). Besides, a normal low-fat diet supplemented 
with EPA + DHA prevented LV hypertrophy (Shah et al., 2009). 
Another experimental study showed that fish oil-enriched diet (5%) 
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prevented LV hypertrophy, increased serum adiponectin concen-
tration, and suppressed inflammatory markers compared to corn 
oil diet (5%) (Halade, Williams, Lindsey, & Fernandes, 2011). A large 
population-based study showed that low adiponectin levels could be 
associated with higher marker of LV hypertrophy (Pääkkö, Ukkola, 
Ikäheimo, & Kesäniemi, 2010).
Adiponectin has been proposed as a marker of peroxisome pro-
liferator-activated receptor-gamma (PPAR-γ) activity (Wagner et al., 
2009) and also a mediator of multiple effects of PPAR-γ (Bouskila, 
Pajvani, & Scherer, 2005) and PPAR-α (Tsuchida et al., 2005). PPAR-γ 
mRNA was decreased significantly in AF compared to non-AF 
 individuals, and also in persistent AF compared to the paroxysmal 
type (Chen et al., 2009). PPAR-γ agonists, such as pioglitazone, reduce 
atrial remodeling and AF duration significantly, potentially through 
antioxidant, anti-inflammatory, and anti-apoptotic mechanisms (Liu, 
Liao, Yang, & Tang, 2016; Xu et al., 2012). Omega-3 fatty acids are 
natural agonists of PPAR-γ and PPAR-α (Grygiel-Górniak, 2014).
Adiponectin could also inhibit angiotensin II-induced cardiac in-
flammation and fibrosis by increasing macrophage autophagy and 
up-regulation of anti-inflammatory mediators (Fujita et al., 2008; Qi, 




pControl (n = 40) Fish oil (n = 40)
Age, years (Mean ± SD) 69.7 ± 7.7 68.6 ± 8.3 .523*
Male, n (%) 19 (47.5) 18 (45) >.9**
Diabetes, n (%) 11 (27.5) 11 (27.5) >.9**
Metformin, n (%) 9 (22.5) 9 (22.5) >.9**
Hypercholesterolemia, n (%) 22 (55) 22 (55) >.9**
Atorvastatin, n (%) 19 (47.5) 22 (55) .655**
Dietary intake (Mean ± SD)
Energy (kcal/day) 1,453.8 ± 543.7 1,319.8 ± 443.1 .248***
Protein (g/day) 57.2 ± 26.9 48.8 ± 22.3 .148***
Fat (g/day) 40.7 ± 21.3 36.5 ± 15.9 .641***
Carbohydrate (g/day) 220.6 ± 88.8 189.6 ± 80.1 .117***
EPA (mg/day) 0.02 ± 0.7 0.02 ± 0.7 .542***
DHA (mg/day) 0.7 ± 0.2 0.7 ± 0.2 .580***
ALA (mg/day) 0.22 ± 0.2 0.24 ± 0.2 .791***
Note: Data are presented as mean ± SD or frequency (%).
*Based on independent samples t test. 
**Based on chi-square test. 
***Based on Mann–Whitney test. 
TA B L E  1   Baseline characteristics of 
the study participants
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Jia, Li, Li, & Du, 2014). Low circulatory levels of adiponectin con-
tribute to insulin resistance and endothelial vascular dysfunction 
(Goldstein & Scalia, 2004), which could be involved in AF pathogen-
esis (Abed & Wittert, 2013; Goudis et al., 2015; O'Neal et al., 2014).
Accordingly, these studies suggest that despite some observa-
tional studies indicating a direct relationship between adiponectin 
and higher risk of AF in a population-based cohort (Macheret et al., 
2015) and after catheter ablation in patients with paroxysmal AF 
(Kim et al., 2017), this peptide may modulate pathophysiological 
pathways in AF. Higher adiponectin levels in those studies might play 
a compensatory role to control AF.
In the current study, ADMA serum concentration decreased in 
patients with persistent AF following 2 g/day fish oil supplementa-
tion for 8 weeks.
It has been reported that serum ADMA levels decreased fol-








pMean ± SD Mean ± SD Lower Upper
Adiponectin (µg/ml)
Before 12.38 ± 7 12.34 ± 6.8 0.04 −3.032 3.111 .979*
After 11.88 ± 6.94 13.15 ± 7.33 −1.309 −2.453 −0.164 .026**
Change 0.51 ± 2.37 −0.8 ± 2.74 1.31 0.168 2.452 .025*
p*** 0.184 0.072     
ADMA (µmol/L)
Before 0.69 ± 0.13 0.64 ± 0.13 0.049 −0.008 0.106 .088*
After 0.72 ± 0.15 0.6 ± 0.13 0.104 0.043 0.164 .001**
Change −0.03 ± 0.17 0.05 ± 0.14 −0.072 −0.142 −0.004 .04*
p*** 0.339 0.04     
Note: p values in the rows refer to pre- to post-differences within the each study group.
*Based on independent samples t test. 
**Adjusted for baseline values based on ANCOVA. 
***Based on paired samples test. 
TA B L E  2   Changes in adiponectin 
and ADMA concentrations in patients 
with AF before and following 8-week 








pMean ± SD Mean ± SD Lower Upper
Weight (kg)
Before 73.8 ± 12.9 73.6 ± 13.3 0.23 −5.604 6.064 .938*
After 73.7 ± 13 72.6 ± 13.3 0.927 0.095 1.758 .029**
Change 0.06 ± 1.74 0.99 ± 1.97 −0.925 −1.751 −0.099 .029*
p*** 0.821 0.003     
Body mass index (kg/m2)
Before 29.2 ± 4.2 29 ± 4.9 0.164 −1.887 2.215 .874*
After 29.2 ± 4.3 28.6 ± 4.8 0.382 0.04 0.725 .029**
Change 0.03 ± 0.7 0.4 ± 0.84 −0.378 −0.722 −0.034 .032*
p*** 0.826 0.004     
Waist circumference (cm)
Before 100.3 ± 8.9 102.3 ± 16 −1.963 −7.715 3.79 .499*
After 100.2 ± 8.8 99.9 ± 16.2 2.321 1.517 3.126 <.001**
Change 0.1 ± 1.34 2.42 ± 2.15 −2.32 −3.119 −1.521 <.001*
p*** 0.640 <0.001     
Note: p values in the rows refer to pre- to post-differences within the each study group.
*Based on independent samples on t test. 
**Adjusted for the baseline values based on ANCOVA. 
***Based on paired samples test. 
TA B L E  3   Changes in anthropometric 
indexes in patients with AF before and 
following 8-week supplementation with 
fish oil
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of cerebral infarction (Hagiwara, Nishiyama, & Katayama, 2011). 
However, 1-month supplementation with 1 g/day n-3 PUFAs in 
patients with acute myocardial infarction (Haberka et al., 2011) or 
2.4 g/day n-3 PUFAs for 36 months in men with hypercholesterol-
emia (Eid et al., 2006) did not affect ADMA levels.
However, these studies had different designs and pathophysio-
logical backgrounds and little is known about the effect of n-3 fatty 
acids on ADMA concentration in AF.
Asymmetric dimethylarginine has been proposed to have prog-
nostic value in determining AF in high-risk patients (Stamboul et al., 
2015) and the adverse events such as mortality and stroke in AF 
(Chao et al., 2013; Horowitz et al., 2018). Treatment with 10 mg daily 
rosuvastatin for 3 months following elective electrical cardioversion 
decreased recurrence of AF through reduction of ADMA levels (Xia, 
Yin, Li, Song, & Qu, 2009). ADMA might be involved in atrial remod-
eling. Higher ADMA levels were correlated with high incidence of 
non-pulmonary veins ectopies, which were predictive of AF (Yang 
et al., 2011). Increased ADMA concentration in AF could be associ-
ated with NO deficiency, which in turn leads to cardiomyocyte apop-
tosis (Feng et al., 2002). ADMA has been suggested as a link between 
AF with oxidative stress and inflammation, endothelial dysfunction, 
and atherosclerosis (Chao et al., 2013). Inflammation is involved in 
AF pathogenesis (Abed & Wittert, 2013; Goudis et al., 2015). ADMA 
is considered a determinant and biochemical measure of endothelial 
dysfunction (Paiva et al., 2010), which might also contribute to AF 
(O'Neal et al., 2014).
Adiponectin and ADMA are adipose-derived factors. Thus, it might 
be speculated that their changes in this study originated from decrease 
in anthropometric indexes not fish oil supplementation. However, it 
should be considered that changes in weight and BMI, although statis-
tically significant, are negligible and clinically irrelevant. The potential 
effect of BMI and waist circumference changes on adiponectin and 
ADMA was also considered in statistical analysis. Additionally, con-
sidering the BMI cutoff of more than 25 kg/m2 confined the effect of 
weight status on adipokines’ changes and was a strength of this study 
as many patients with AF are overweight or obese.
Some limitations are needed to be mentioned for this trial. Our 
study provided observations on changes of adiponectin and ADMA 
serum concentrations following fish oil supplementation in patients 
with persistent AF, but did not directly evaluate clinical outcomes 
and mechanisms associated with adiponectin and ADMA. However, 
considering the important and close relationship of these factors 
with mechanisms involved in AF pathogenesis and the predictive 
and prognostic role of ADMA in AF, the corresponding changes fol-
lowing fish oil supplementation are considerable and should be in-
vestigated with more details in future studies.
5  | CONCLUSION
Eight weeks of fish oil supplementation led to increase in serum adi-
ponectin and decrease in serum ADMA concentrations in patients 
with persistent AF.
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